L Bengrine-Lefevre, P Afchain… - La Revue de …, 2011 - ncbi.nlm.nih.gov A 52-year-old woman, with a metastatic breast cancer, presented with a nasal septum perforation while receiving a treatment combining paclitaxel and bevacizumab. This is the fifth reported case of nasal septum perforation probably related to an anti-angiogenic therapy. A literature ...
DG Power… - Medical Oncology, 2011 - Springer Abstract The use of targeted/biologic therapies is now commonplace in the treatment of malignant and non- malignant diseases. The novel mode of action of these drugs has resulted in unpredictable and in some cases unexpected side effects. Given the widespread use of bevacizumab ... Cited by 4 - Related articles - All 4 versions
F Petrelli, M Cabiddu, C Barbara… - Breast Cancer, 2011 - Springer Abstract Nasal septum perforation is a rare but described complication of the anti-angiogenetic agent bevacizumab. This is the case of a 48-year-old female breast cancer patient, who developed a nasal septum perforation during treatment with paclitaxel and bevacizumab for ... Related articles - All 2 versions
JAB Ramiscal… - Acta Oncologica, 2011 - informahealthcare.com ... These investigators concluded, “A high incidence of nasalseptumperforation has been shown in patients with breast cancer receiving bevacizumab together with chemotherapy.”. ... Bevacizumab-induced nasalseptumperforation. ... Cited by 2 - Related articles - All 3 versions
A Teymoortash, S Hoch, B Eivazi… - American Journal of …, 2011 - ingentaconnect.com ... Keywords: Closure,; mucosal flap,; nasal septal perforation,; nasalseptum,; repair,; technique. ... Figure 2. Figure 2. Click to view. Figure 2. Schematic presentation of the surgical technique for flap removal from the left nasal cavity in eight steps. (a) Perforation of the nasalseptum; (b ... All 2 versions